Concourse Financial Group Securities, Inc. Cabaletta Bio, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$3.94 - $8.24 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$7.22 - $18.82 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$16.79 - $25.38 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$12.21 - $23.36 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$11.84 - $18.65 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$11.84 - $18.65 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$7.65 - $13.95 $0 - $0
Q1 2023 May 15, 2023	BUY	$7.08 - $12.62 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$0.64 - $9.3 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$0.63 - $2.05 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$0.99 - $2.11 $0 - $0
Q1 2022 May 09, 2022	BUY	$1.68 - $3.92 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$3.36 - $14.64 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$7.0 - $12.5 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$7.2 - $11.73 $0 - $0
Q1 2021 May 13, 2021	BUY	$10.39 - $14.53 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$9.81 - $15.8 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$9.71 - $14.41 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$6.39 - $11.28 $0 - $0
Q1 2020 May 13, 2020	BUY	$6.0 - $18.67 $0 - $0
Q4 2019 Feb 14, 2020	BUY	$7.88 - $17.71 $0 - $0

Others Institutions Holding CABA

# of Institutions

126

Shares Held

47.9M

Call Options Held

202K

Put Options Held

110K

Jennison Associates LLC

5.63M
Shares

$12.9 Million
0.02% of portfolio
Black Rock Inc. New York, NY

4.76M
Shares

$10.9 Million
0.0% of portfolio
Fred Alger Management, LLC New York, NY

4.12M
Shares

$9.43 Million
0.1% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

3.67M
Shares

$8.41 Million
0.01% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

3.04M
Shares

$6.95 Million
0.03% of portfolio

View Full List

About Cabaletta Bio, Inc.

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $66.4M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

More about CABA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account